Goodwin Procter advised Goldman Sachs & Co. LLC and the other underwriters on the deal. Omega Therapeutics, Inc. (Nasdaq: OMGA), a development-stage biotechnology company leveraging its OMEGA...
Omega Therapeutics’ $144.6 Million IPO
Tenaya Therapeutics’ $207 Million Initial Public Offering
Davis Polk advised the representatives of the several underwriters in the offering while Wilson Sonsini Goodrich & Rosati represented Tenaya Therapeutics. Tenaya Therapeutics, Inc. executed the initial...
Xponential Fitness’ $120 Million Initial Public Offering
Davis Polk advised Xponential Fitness in its IPO, while Latham & Watkins represented the underwriters. Xponential Fitness, Inc. executed its $120 million initial public offering of 10,000,000...
Sight Sciences’ $240 Million Initial Public Offering
Latham & Watkins LLP represented Sight Sciences, Inc. in the offering, while Davis Polk advised the representatives of the several underwriters. Sight Sciences, Inc. executed its initial public...
Blend’s IPO
Wilson Sonsini Goodrich & Rosati advised Blend on the deal while Goodwin Procter represented the underwriters. Blend Labs, Inc. announced the pricing of its initial public...
Alpha Tau’s Business Combination with Healthcare Capital Corp.
Latham & Watkins LLP represented Alpha Tau in the transaction, while Winston & Strawn represented the placement agent. Alpha Tau Medical Limited, the developer of the...
Aligos Therapeutics’ $83.6 Million Public Offering
Latham & Watkins LLP represented Aligos Therapeutics, while Davis Polk advised the representatives of the several underwriters in the offering. Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced...
SentinelOne’s IPO and Concurrent Private Placement
Fenwick & West LLP advised SentinelOne on the deal, while Latham & Watkins LLP represents the underwriters. SentinelOne, an autonomous cybersecurity platform company, announced its initial public...
Monte Rosa Therapeutics’ $222.3 Million Initial Public Offering
Latham & Watkins LLP represented the underwriters in the offering. Monte Rosa Therapeutics, Inc. executed its initial public offering of 11,700,000 shares of common stock at a...
Century Therapeutics’ $242.7 Million Initial Public Offering
Davis Polk advised the representatives of the several underwriters in the offering. Century Therapeutics, Inc. executed the $242.7 million initial public offering of 12,132,500 shares of...
RAPT Therapeutics’ $143.7 Million Equity Offering
Cooley advised RAPT Therapeutics, while Davis Polk advised the joint book-running managers in the offering. with a $143.7 million SEC-registered follow-on offering of 4,356,060 shares of...
Duolingo’s Initial Public Offering
Latham & Watkins represented Duolingo, while Skadden, Arps, Slate, Meagher & Flom advised the bookrunners on the deal. Duolingo has publicly filed a registration statement with the U.S....